Product Partnering

Product Partnering is our major thrust area and to facilitate this process. We partner major pharmaceutical companies in India & abroad as a reliable and efficient contract manufacturer.

Articles from Deus Medical


PROVIMED 25 (Mesterolone) for the Treatment of Male Infertility

PROVIMED 25 (Mesterolone) belongs to the group of medicines known as androgens, which work by supplementing your body's natural male sex hormones. Meaning, that PROVIMED 25 (Mesterolone) tablets are prescribed for men to treat disorders where the body does not make enough natural androgen. PROVIMED 25 (Mesterolone) is a new androgen used for Male infertility, Testosterone deficiency, and other conditions.

In general, hormonal treatment of male infertility has mainly involved the use of androgens and gonadotropins for disturbances in spermatogenesis. That is very important to note, that the treatment of male infertility depends upon the underlying cause, which includes:

  • Physical problems with the testicles
  • Blockages in the ducts that carry sperm
  • Hormone problems
  • A history of high fevers or mumps
  • Genetic disorders
  • Lifestyle or environmental factors

It is possible that Male Infertility shows no physical symptoms and still be present in a patient. Many infertile couples have more than one cause of infertility. About a third of the cases, infertility is because of a problem with the man. One-third of the time, it is a problem with the woman. That is necessary for a couple to see a doctor together. In some cases, a cause is never identified. It might take several tests to outline the cause of infertility. Usually, several months to years of treatment are necessary to achieve fertility.

During the treatment with PROVIMED 25 (Mesterolone), that is important to have regular blood tests and examinations of prostate and breasts. The reason is that the treatment may increase the rate of growth of some types of cancer.

A prospective randomized double-blind study was undertaken to determine the effect on male fertility after 6 months' treatment with the synthetic androgen PROVIMED 25 (Mesterolone) . The study was performed in seven centres and 248 infertile couples were recruited randomly. All couples were investigated according to the standardized WHO protocol--Investigation and Diagnosis of the Infertile Couple. During this investigation, 157 couples were selected in whom the male diagnosis was a primary idiopathic testicular failure or idiopathic low sperm motility; while the female partner had no visible cause for infertility or was under successful treatment for a minor endocrine problem. Men received either 150 or 75 mg Mesterolone daily or placebo. Results were assessed in terms of semen characteristics and the partner's pregnancy rate.

8 months after the study, pregnancy rates among all couples were 9 +/- 3% (+/- standard error), 12 +/- 4% in the placebo, and 16 +/- 4% in 75 and 150 mg PROVIMED 25 (Mesterolone) groups, respectively. Among 157 couples satisfying the strict eligibility criteria, the pregnancy rates were 11 +/- 5% in the placebo group, and 12 +/- 5% and 19 +/- 6%, in 75 and 150 mg PROVIMED 25 (Mesterolone) groups, respectively. There were no significant changes in semen quality during the study, apart from an increase in sperm concentration 3 months after the start of treatment. That is curious, but the increase was greatest among the placebo-treated group, although it did not differ significantly between treatment groups.